Orshe

Also: worries about lung-screening trial after-effects; Pfizer to link with UCSF on research; lawmakers urge the FDA to act on caffeinated alcoholic drinks.

Read more:  A.M. Vitals: Xerox and Other Tech Firms Aiming for Insurance Exchange Contracts

Pfizer’s results — and management’s rosy outlook — depended heavily on Wyeth.

Go here to read the rest: The Bottom Line on Why Pfizer Bought Wyeth

Also: AMA warns on looming Medicare cuts; Pfizer recalls more Lipitor on musty bottle odor; plague outbreaks originated in China.

Read more: A.M. Vitals: Roche Gearing Up for Generic Battle

Even after buying King for $3.6 billion and Wyeth for $68 billion, Pfizer will still need to stay in the M&A hunt.

Read the original here: With King in the Cart, Pfizer’s Not Done Shopping

A family argues it should be able to sue Pfizer’s Wyeth unit over allegations that the drug maker could have, but didn’t, market a safer vaccine.

Excerpt from:  Supreme Court Hears Arguments on Vaccine Liability Law

King’s products include new formulations of pain treatments, an emergency drug delivery business and an animal health business.

Read the original: Pfizer to Pay $3.6 Billion for King Pharmaceuticals

George Stahl discusses what Pfizer hopes to gain by buying King Pharmaceuticals.

View original here:  News Hub: Pfizer to Buy King Pharmaceuticals/a>

Pfizer announced Monday that it’s giving away 500,000 free bottles of Advil to people who clear their medicine cabinet of expired or recalled medicines.

Read more:  Steel Cage Match: Advil vs. Tylenol Edition

Growth in the animal health market is expected to continue at 5% growth for coming years.

Excerpt from: Pfizer Wants to Be the IBM of Animal Health

Genetically modified pig may be coming to a menu near you.

Excerpt from:  Can This Pig Fly?